Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;6(6):e19852.
doi: 10.1371/journal.pone.0019852. Epub 2011 Jun 6.

Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study

Affiliations

Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study

Christian Herder et al. PLoS One. 2011.

Abstract

Background: This study compares inflammation-related biomarkers with established cardiometabolic risk factors in the prediction of incident type 2 diabetes and incident coronary events in a prospective case-cohort study within the population-based MONICA/KORA Augsburg cohort.

Methods and findings: Analyses for type 2 diabetes are based on 436 individuals with and 1410 individuals without incident diabetes. Analyses for coronary events are based on 314 individuals with and 1659 individuals without incident coronary events. Mean follow-up times were almost 11 years. Areas under the receiver-operating characteristic curve (AUC), changes in Akaike's information criterion (ΔAIC), integrated discrimination improvement (IDI) and net reclassification index (NRI) were calculated for different models. A basic model consisting of age, sex and survey predicted type 2 diabetes with an AUC of 0.690. Addition of 13 inflammation-related biomarkers (CRP, IL-6, IL-18, MIF, MCP-1/CCL2, IL-8/CXCL8, IP-10/CXCL10, adiponectin, leptin, RANTES/CCL5, TGF-β1, sE-selectin, sICAM-1; all measured in nonfasting serum) increased the AUC to 0.801, whereas addition of cardiometabolic risk factors (BMI, systolic blood pressure, ratio total/HDL-cholesterol, smoking, alcohol, physical activity, parental diabetes) increased the AUC to 0.803 (ΔAUC [95% CI] 0.111 [0.092-0.149] and 0.113 [0.093-0.149], respectively, compared to the basic model). The combination of all inflammation-related biomarkers and cardiometabolic risk factors yielded a further increase in AUC to 0.847 (ΔAUC [95% CI] 0.044 [0.028-0.066] compared to the cardiometabolic risk model). Corresponding AUCs for incident coronary events were 0.807, 0.825 (ΔAUC [95% CI] 0.018 [0.013-0.038] compared to the basic model), 0.845 (ΔAUC [95% CI] 0.038 [0.028-0.059] compared to the basic model) and 0.851 (ΔAUC [95% CI] 0.006 [0.003-0.021] compared to the cardiometabolic risk model), respectively.

Conclusions: Inclusion of multiple inflammation-related biomarkers into a basic model and into a model including cardiometabolic risk factors significantly improved the prediction of type 2 diabetes and coronary events, although the improvement was less pronounced for the latter endpoint.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Hazard ratios (95% CI) for incident type 2 diabetes for z-transformed inflammation-related biomarkers.
Solid lines (model 1): each biomarker adjusted for age, sex and survey. Dashed lines (model 2): each biomarker adjusted for age, sex, survey, BMI, systolic blood pressure, ratio of total cholesterol to HDL cholesterol, smoking, alcohol consumption, physical activity and parental diabetes.
Figure 2
Figure 2. Hazard ratios (95% CI) for incident coronary events for z-transformed inflammation-related biomarkers.
Solid lines (model 1): each biomarker adjusted for age, sex and survey. Dashed lines (model 2): each biomarker adjusted for age, sex, survey, BMI, systolic blood pressure, ratio of total cholesterol to HDL cholesterol, smoking, alcohol consumption, physical activity, parental myocardial infarction and prevalent diabetes.

References

    1. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48:1038–1050. - PubMed
    1. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526. - PubMed
    1. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152:346–357. - PMC - PubMed
    1. Sattar N, Wannamethee SG, Forouhi NG. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia. 2008;51:926–940. - PubMed
    1. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE. 2010;5(4):e10100. - PMC - PubMed

Publication types

MeSH terms